2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1634

Genome-Wide Transcriptional Profiling Of Isolated Immune Cell Populations From SLE Patients With Different Ancestral Backgrounds
Abstract Number: 162

Genotypic and Haplotypic Effects Of 7 Single-Nucleotide Polymorphisms In the CRP Gene On Levels Of C-Reactive Protein and DAS28 In a Cohort Of 180 Untreated Newly Diagnosed Rheumatoid Arthritis Patients (OPERA Study)
Abstract Number: 1993

Geographic Variations Of Gout Epidemiology In The United Kingdom: A Nationwide Population Study
Abstract Number: 2218

Gingival Stem Cells Suppress Osteoclast Formation and Bone Erosion In CIA Through CD39 Signal
Abstract Number: 87

Global and Country Specific Burden Of Musculoskeletal Disorders:a Report From The Global Burden Of Diseases Musculoskeletal Expert Group
Abstract Number: 1880

Global Gene Expression Profiles Reveal Genetic Signatures Of Kawasaki Disease and Disease Outcome
Abstract Number: 2290

Global Metabolite Profiling Of Synovial Fluids From Different Forms Of Inflammatory Arthritis For The Identification Of Putative Biomarker In Rheumatoid Arthritis
Abstract Number: 2099

Global Postural Reeducation To TREAT Chronic LOW Back PAIN: Randomized, Controlled Trial
Abstract Number: 55

Glucocorticoid Receptor Modulator Compound A Does Not Induce Leptin In Human Osteoarthritic Synovial Fibroblasts and In Dedifferentiated Chondrocytes
Abstract Number: 746

Glucocorticoid Treatment and Damage In The Antineutrophil- Cytoplasm Antibody Associated Vasculitides
Abstract Number: 1052

Glucocorticosteroids and Mortality Risk In Rheumatoid Arthritis – Results Of a Population Based Study
Abstract Number: 2113

Glucosamine–Chondroitin Sulfate Reduces Pain, Disability and Non-Steroidal Anti-Inflammatory Drug consumption In Patients With Chronic Low Back Pain: A Large, Community-Based, Pilot, Open Prospective Study
Abstract Number: 281

GO-Kids Imaging Substudy: MRI Treatment Response To 30 Mg/m² 4-Weekly Subcutaneous injections Of Golimumab In Children With Polyarticular JIA – Preliminary Results Of The Open Label Portion
Abstract Number: 477

Golimumab Improves Patient-Reported Outcomes In Patients With Active Rheumatoid Arthritis
Abstract Number: 1456

Golimumab Levels, Anti-Drug Antibodies and Clinical Response In Rheumatoid Arthritis Patients At 28 Week Of Follow-Up

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].